Squawk on the Street Cramer's Morning Take: Bristol Meyers & Eli Lilly 1/16/25
4 snips
Jan 16, 2025 Jim and Jeff spotlight a promising biopharmaceutical company's potential, particularly in treating major mental health issues. They discuss advancements in drug treatments, linking them to broader societal challenges like schizophrenia and homelessness. The duo also reflects on the cautious market climate while highlighting opportunities in emerging markets, notably China and India. Join the CNBC Investing Club for deeper insights into these exciting market trends!
AI Snips
Chapters
Transcript
Episode notes
Buy Bristol Myers
- Consider buying Bristol Myers stock aggressively.
- Cramer believes it's dramatically undervalued and positioned for growth in 2026.
Bristol Myers Drug Potential
- Bristol Myers' new drug has no side effects and may even address homelessness, according to the mayor of San Francisco.
- A significant portion of the homeless population is schizophrenic.
Lilly's Q4 and 2025 Outlook
- Eli Lilly's Q4 numbers were soft due to distribution issues, but 2025 guidance is good.
- CEO David Ricks disputes claims about Mounjaro's one-year efficacy and is bullish on its future.